Pharmaceutical manufacturer
H.R. 2853 BLOCKING Act of 2021 (All sections of full text). P.L. 117-169, Inflation Reduction Act of 2022 (All sections of full text). S. 2910, Expanding Access to Low-Cost Generics Act of 2021 (All sections of full text). Discussions regarding S. 3799, PREVENT Pandemics Act of 2022. Discussions regarding the reauthorization of Generic Drug User Fee Amendments included in P.L.117-95, Extension of Continuing Appropriations Act. Discussions regarding the approval of generic drugs. Discussions regarding improved education about digital health care. Monitored the implementation of P.L.117-7, To prevent across-the-board direct spending cuts, and for other purposes. Monitored Medicare and prescription drug changes. Monitored discussions related to mental health legislation. Monitored HR 7377, Modernizing Therapeutic Equivalence Rating Determination Act. Monitored S. 1463, Modernizing Therapeutic Equivalence Rating Determination Act. Monitored discussions related to FDA 'skinny labelling' issue.
HCR - Health Issues CPT - Copyright/Patent/Trademark
136 - Centers For Medicare and Medicaid Services (CMS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 12 - White House Office
THE SMITH-FREE GROUP, LLC
1401 K Street NW Suite 1200, Washington, DC, 20005, US
JACK S DEUSER MICHAEL A. GAFFIN ROBERT HICKMOTT TREVOR W. KOLEGO MICHAEL A. GAFFIN